<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902575</url>
  </required_header>
  <id_info>
    <org_study_id>FUGES-05</org_study_id>
    <nct_id>NCT02902575</nct_id>
  </id_info>
  <brief_title>The Safety and Feasibility of Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer After Neoadjuvant Chemotherapy</brief_title>
  <official_title>The Safety and Feasibility of Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer After Neoadjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the safety, feasibility, long-term and&#xD;
      oncologicaloutcomes of laparoscopic-assisted gastrectomy for advanced Gastric Cancer after&#xD;
      neoadjuvant chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective single-arm study designed to further evaluate laparoscopic-assisted gastrectomy&#xD;
      for advanced Gastric Cancer after neoadjuvant chemotherapy will be performed, to evaluate the&#xD;
      safety, feasibility, long-term and oncological outcomes. The evaluation parameters are&#xD;
      perioperative mobility and mortality, perioperative clinical efficacy, postoperative life&#xD;
      quality, immune function and 3-year survival and recurrence rates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Actual">November 30, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>laparoscopic-assisted gastrectomy for advanced Gastric Cancer after neoadjuvant chemotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morbidity</measure>
    <time_frame>30 days</time_frame>
    <description>The early postoperative complication are defined as the event observed within 30 days after surgery.Postoperative complications were graded according to the Clavien-Dindo classiÔ¨Åcation system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological response</measure>
    <time_frame>30 days</time_frame>
    <description>Pathological response grading was performed according to the Becker TRG system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response</measure>
    <time_frame>30 days</time_frame>
    <description>Radiological response and progression were assessed according to RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year disease free survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>3-year disease free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>3-year overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year recurrence pattern</measure>
    <time_frame>36 months</time_frame>
    <description>Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>The early mortality are defined as the event observed within 30 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first ambulation</measure>
    <time_frame>10 days</time_frame>
    <description>The data of postoperative recovery course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of combined organ resection</measure>
    <time_frame>1 day</time_frame>
    <description>Combined organ resection performing by severe injury or abdominal adhesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of lymph node dissection</measure>
    <time_frame>1 day</time_frame>
    <description>The number of lymph node dissection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of weight</measure>
    <time_frame>12 months</time_frame>
    <description>The variation of weight on postoperative 3, 6, 9 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The daily highest body temperature</measure>
    <time_frame>7 days</time_frame>
    <description>The daily highest body temperature before discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first flatus</measure>
    <time_frame>10 days</time_frame>
    <description>Time to first flatus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first liquid diet</measure>
    <time_frame>10 days</time_frame>
    <description>Time to first liquid diet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to soft diet</measure>
    <time_frame>10 days</time_frame>
    <description>Time to soft diet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scale the amount of abdominal drainage</measure>
    <time_frame>10 days</time_frame>
    <description>Scale the amount of abdominal drainage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>10 days</time_frame>
    <description>Blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of positive lymph nodes</measure>
    <time_frame>1 days</time_frame>
    <description>The number of positive lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative lymph node dissection time</measure>
    <time_frame>1 days</time_frame>
    <description>intraoperative lymph node dissection time includes infrapyloric area lymph node,suprapancreatic area lymph node,splenic hilar area lymph node, cardial area lymph node and jejunal lymph nodes adjacent to the anastomosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>1 days</time_frame>
    <description>Intraoperative blood loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of operation</measure>
    <time_frame>1 day</time_frame>
    <description>Time of operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative injury</measure>
    <time_frame>1 days</time_frame>
    <description>Intraoperative injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of use of titanium clip</measure>
    <time_frame>1 days</time_frame>
    <description>The amount of use of titanium clip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of conversion to laparotomy</measure>
    <time_frame>1 days</time_frame>
    <description>The rate of conversion to laparotomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of albumin</measure>
    <time_frame>12 month</time_frame>
    <description>The variation of albumin on postoperative 3, 6, 9 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The results of endoscopy</measure>
    <time_frame>12 month</time_frame>
    <description>the results of endoscopy on postoperative 3 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The values of white blood cell count</measure>
    <time_frame>7 days</time_frame>
    <description>the values of white blood cell count from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The values of hemoglobin</measure>
    <time_frame>7 days</time_frame>
    <description>the values of hemoglobin from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The values of C-reactive protein</measure>
    <time_frame>7 days</time_frame>
    <description>the values of C-reactive protein from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The values of prealbumin</measure>
    <time_frame>7 days</time_frame>
    <description>the values of prealbumin from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>10 days</time_frame>
    <description>Duration of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late postoperative complication</measure>
    <time_frame>36 months</time_frame>
    <description>The late postoperative complication was defined as the event observed within the period from postoperative day 31th to the end of month 36th.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Adverse events (AEs) of neoadjuvant chemotherapy were assessed at each visit per the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>Laparoscopic-assisted Gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic-assisted gastrectomy with D2 lymphadenectomy</intervention_name>
    <description>After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed with curative treated intent.The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy</description>
    <arm_group_label>Laparoscopic-assisted Gastrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age from 18 to 75 years&#xD;
&#xD;
          -  Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or&#xD;
             poorly differentiated) confirmed pathologically by endoscopic biopsy&#xD;
&#xD;
          -  cT2-4aN+M0 at preoperative evaluation according to the American Joint Committee on&#xD;
             Cancer (AJCC) Cancer Staging Manual Seventh Edition&#xD;
&#xD;
          -  No distant metastasis is observed. And the spleen, pancreas or other adjacent organs&#xD;
             are not involved by the tumor.&#xD;
&#xD;
          -  Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)&#xD;
&#xD;
          -  American Society of Anesthesiology score (ASA) class I, II, or III&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women during pregnancy or breast-feeding&#xD;
&#xD;
          -  Severe mental disorder&#xD;
&#xD;
          -  History of previous upper abdominal surgery (except laparoscopic cholecystectomy,&#xD;
             previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal&#xD;
             dissection)&#xD;
&#xD;
          -  History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal&#xD;
             dissection&#xD;
&#xD;
          -  History of other malignant disease within past five years&#xD;
&#xD;
          -  History of unstable angina or myocardial infarction within past six months&#xD;
&#xD;
          -  History of cerebrovascular accident within past six months&#xD;
&#xD;
          -  History of continuous systematic administration of corticosteroids within one month&#xD;
&#xD;
          -  Requirement of simultaneous surgery for other disease&#xD;
&#xD;
          -  Emergency surgery due to complication (bleeding, obstruction or perforation) caused by&#xD;
             gastric cancer&#xD;
&#xD;
          -  FEV1&lt;50% of predicted values&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 11, 2016</study_first_submitted>
  <study_first_submitted_qc>September 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Chang-Ming Huang, Prof.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Laparoscopy</keyword>
  <keyword>Advanced Gastric Cancer</keyword>
  <keyword>Neoadjuvant Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

